Literature DB >> 2233451

Invasive disease due to Salmonella virchow: a north Queensland problem.

L R Ashdown1, P J Ryan.   

Abstract

Salmonella virchow is the second most commonly isolated salmonella serotype from human sources in Australia, and overseas studies indicate that S. virchow is a significant cause of extraintestinal salmonellosis. The successful management of three infants, two with septicaemia and one with leptomeningitis and septicaemia due to S. virchow, is described. A review of the Townsville General Hospital laboratory records (1978-1988) showed that, among other aspects, S. virchow accounted for 46% of all salmonella septicaemias, further exemplifying the invasive propensity of this serotype. Information obtained from various sources, after crude analyses, demonstrates that more than 90% of S. virchow infections in humans in Australia occur in Queensland, and that most (greater than 78% in 1987) of those infections in Queensland come from a coastal zone north of Bundaberg, with the highest concentration (0.4 per 1000 persons) occurring in the Cairns region.

Entities:  

Mesh:

Year:  1990        PMID: 2233451     DOI: 10.5694/j.1326-5377.1990.tb136941.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Salmonella virchow PT 26 infection in England and Wales: a case control study investigating an increase in cases during 1994.

Authors:  L J Willocks; D Morgan; F Sufi; L R Ward; H E Patrick
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

2.  Systemic infections in three infants due to a lactose-fermenting strain of Salmonella virchow.

Authors:  J Ruiz; M L Núñez; M A Sempere; J Díaz; J Gómez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

3.  Genome analysis and CRISPR typing of Salmonella enterica serovar Virchow.

Authors:  Nathan L Bachmann; Nicola K Petty; Nouri L Ben Zakour; Jan M Szubert; John Savill; Scott A Beatson
Journal:  BMC Genomics       Date:  2014-05-21       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.